Shares of Biomarin Pharmaceutical Inc. topped $80 Thursday morning, one day after hitting a previous 52-week high. Although the stock (NASDAQ:BMRN) lost some lift late in the day, closing up 90 cents at $78.39, the uptick still pushed the company’s market cap to $11 billion. Read More
The sky is getting crowded as biotech companies on the initial public offering (IPO) runway continue to take off with increasing regularity. The latest to get airborne is Cambridge, Mass.-based Acceleron Pharma Inc., which priced its IPO Thursday. Read More
With the Supreme Court beginning its next session later this month, drugmakers are looking to the justices for guidance in shareholder, whistleblower and patent infringement cases while seeking protection from punitive damages and some civil suits. Read More
BOSTON – “How Far Can You Go with Angel Investors?” asked the title of a panel discussion that included two financiers and two company chiefs at the Biopharm America conference. Read More
Protagonist Therapeutics Inc. added a new investor, Pharmstandard International SA, to its previously announced Series B financing, boosting its raise by $4 million, for a total of $18 million. The funds will support Protagonist’s pipeline of orally stable peptides for inflammatory bowel disease (IBD) and other gastrointestinal (GI) disorders. Read More
• Argen-x BV, of Breda, the Netherlands, said it attained a milestone in its SIMPLE Antibody research and product development collaboration with the Human Genetic Therapies division of Dublin-based Shire plc, triggering an undisclosed payment from Shire. Read More
• Exosome Diagnostics Inc., of New York, said it entered a collaboration with Eli Lilly and Co., of Indianapolis, for biomarker discovery and validation using Exosome’s EXO50 nucleic acid extraction kit. Read More
• Oncomed Pharmaceuticals Inc., of Redwood City, Calif., said it started a Phase Ib/II trial of cancer stem cell candidate demcizumab (OMP-21M18) in ovarian cancer. Read More
